In the current scenario, the rapid spread of COVID-19 across major regions has created significant opportunities for the plasma therapy market. Scientific studies have shown that plasma therapy, when ...

NLS Pharmaceutics ( (NLSP) ) has shared an update.

NLS Pharmaceutics (NLSP) and Kadimastem, announced in collaboration with iTolerance, that a request for a Pre-Investigational New Drug meeting ...

The global cell therapy market size was US$ 7.88 billion in 2021. The global cell therapy market is forecast to grow to US$ 22.9 billion by 2030 by registering a compound annual growth rate (CAGR) of ...

HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure.

Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with ...

Daiichi Sankyo has announced the dosage of the first subject in the randomised Phase III QuANTUM-Wild trial of oral Vanflyta ...

This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 ...

Poseida Therapeutics is known for its allogenic CAR-T therapies that promise “off-the-shelf” treatments that are readily available for patients with certain types of cancers. Roche has been ...